Latest news with #Parkinson's'
Time of India
26-04-2025
- Health
- Time of India
Ryan Reynolds Reflects on Father's Battle with Parkinson's Disease and the Importance of Modern Treatments
Ryan Reynolds, the 'Deadpool' star, opened up about his father's unfortunate demise due to the deadly Parkinson's disease, and wishes things had been different. The actor attended Acadia Pharmaceuticals ' New York City panel for Parkinson's Awareness Month and shed light on his fathers's struggles with hallucinations and delusions. Impact of Parkinson's on Ryan Reynolds' father James Chester, the father of Reynolds, passed away at 74 after battling with Parkinson's for two decades. The 48-year-old actor shed light on his father's diagnosis by stating, 'A man with four children, working class, dealing with a disease that is degenerative and something that will one day render him physically unable to take care of himself or others, that is going to have a profound effect on the psyche. That's not easy,' he said to People. One thing that could've been different The one thing he wishes had been different is that the modern medical treatment given by the pharmaceuticals was available when his father was struggling. He further added that while he was one of the many patients experiencing hallucinations and delusions, Chester might've stated the term 'Parkinson's' probably twice in his entire life. 'He certainly wasn't going to talk about some of the psychological effects it was having on him. And if there was treatment for that, if there was something available back then, I think his whole life would've improved. I think his sense of well-being would've been restored. His sense of reality would've been restored,' Ryan Reynolds added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trade Bitcoin & Ethereum – No Wallet Needed! IC Markets Start Now Undo While Ryan's father had the disorder, his mother had suffered as well, being the sole caregiver. 'She was the primary caregiver for my father. And when you have somebody who's very prideful like that, he's not going to accept help from anyone else. So I feel for them as much as I do the patients,' the actor said. Stay updated with the latest Best Hindi Movies , Best Tamil Movies , Best Telugu Movies , Best english Movies , Best Malayalam Movies
Yahoo
04-04-2025
- Health
- Yahoo
Arvinas' PROTAC halves protein suspected to play role in Parkinson's
A first-in-human trial of Arvinas' investigational Parkinson's' disease therapy, ARV-102, has been able to demonstrate a drop in the multifunctional protein that has been associated with the disease whilst also surpassing the blood-brain barrier. The Phase I single ascending dose (SAD) and multiple ascending dose (MAD) trial (EUCT-2023-507910-28-00) found ARV-102, a proteolysis targeting chimaera (PROTAC) therapy, led to a drop in leucine-rich repeat kinase 2 (LRRK2) across healthy volunteers. LRRK2 is associated with an increased risk of both autosomal dominant Parkinson's disease and Crohn's disease. In the SAD cohort, a single oral dose of at least 60mg of ARV-102, alongside further once daily repeated oral doses of at least 20mg, achieved greater than 50% LRRK2 reduction in the volunteer's cerebral spinal fluid. As well as a more than 90% LRRK2 reduction in the peripheral blood mononuclear cells (PBMCs). Investigation in the MAD cohort is still ongoing. Additional results from the SAD cohort found that ARV-102 at single doses of more than 30mg induced more than 50% decrease in peripheral phosphor-Rab10, a biomarker used to determine the therapy's ability to impact downstream of the blood-brain barrier. Noah Berkowitz, CMO at Arvinas, said: 'The ability of ARV-102 to cross the blood-brain barrier and degrade the LRRK2 protein offers a potentially transformative therapeutic approach in the treatment of devastating neurodegenerative diseases. 'We believe these results support continuing our ARV-102 clinical program and building upon our body of evidence for this lead PROTAC degrader candidate in our neuroscience pipeline.' Results from the randomised, double-blind, placebo-controlled were initially announced as part of the 2025 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) in Vienna, Austria. In the Phase I trial, the therapy was relatively well tolerated, with some adverse events (AEs) reported. Approximately 47 volunteers were recruited across all SAD dose levels with headaches reported in 17.1% of patients. Procedural pain associated with the lumbar puncture occurred in 28.6% of treated volunteers compared to 41.7% in placebo controls. This comes weeks after Arvinas' stock took a 51% after its PROTAC therapy for human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, being developed with pharma giant Pfizer, saw mixed results as it was only able to extend progression-free survival (PFS) in certain patients. The trial was conducted as part of a $2.4bn partnership between the companies. This latest Parkinson's data gives renewed hope to Arvinas for PROTAC therapies. Elsewhere in the field of Parkinson's disease therapies, Cerevance is continuing an ongoing pivotal study of its Parkinson's candidate despite it showing no benefit compared to placebo in a Phase II study. "Arvinas' PROTAC halves protein suspected to play role in Parkinson's" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Express Tribune
17-02-2025
- Entertainment
- Express Tribune
Jake Paul clarifies comment on Mike Tyson's Parkinson's disease: 'I Misspoke'
Jake Paul is walking back a statement he made about boxing legend Mike Tyson after accidentally suggesting that the former heavyweight champion had Parkinson's disease. The internet went into a frenzy after Paul, 27, claimed in a recent interview that psychedelic toad venom 'cured Tyson's Parkinson's' and that it played a role in his return to the ring. However, Paul quickly shut down the speculation, taking to X (formerly Twitter) to clarify his statement. 'Bruh…Mike Tyson didn't have no Parkinson's…WTF. Why the f**k is the internet so stupid for. I misspoke. Meant he used toad to heal his pain. He has spoken about it many times. Just like I do. Just like many do,' he wrote. Bruh…Mike Tyson didn't have no Why the fuck is the internet so stupid for. I misspoke. Meant he used toad to heal his pain. He has spoken about it many times. Just like I do. Just like many do. — Jake Paul (@jakepaul) The clarification comes after Paul's blockbuster fight against Tyson in November, which saw the social media star defeat the boxing icon via unanimous decision at AT&T Stadium. The match was one of the biggest events of Paul's career, but his latest comments on Tyson's health have reignited controversy. While there is no official confirmation that Tyson, 58, has Parkinson's disease, concerns about his health have surfaced in recent months. The former champion experienced a medical scare in May due to an ulcer flare-up, which resulted in a four-month delay of his bout with Paul. Outside of his comments on Tyson, Paul also stirred up another debate—this time about the state of mixed martial arts. Speaking on the All The Smoke Fight podcast, he claimed, 'MMA is not what it was. That's the truth of the matter. Boxing is bigger than ever. The biggest sporting event of the year of 2024 was boxing, whereas MMA is becoming a s**ttier version of boxing.' Paul argued that modern MMA is 'essentially kickboxing' due to the increasing ability of fighters to defend takedowns and their expertise in jiu-jitsu. 'There's no more submissions, really. There's not a lot of takedowns and even if there is, it's f**king boring,' he added. Despite his controversial takes, Paul continues to be a major figure in combat sports, both for his in-ring performances and his unfiltered opinions. With Tyson's health clarified and his stance on MMA making waves, Paul remains at the center of the conversation—whether fans like it or not.
